Pembrolizumab (Pembro) Plus Axitinib (Axi) Versus Sunitinib As First-Line Therapy For Metastatic Renal Cell Carcinoma (Mrcc): Outcomes In The Combined Imdc Intermediate/Poor Risk And Sarcomatoid Subgroups Of The Phase 3 Keynote-426 Study.